Discovery of novel immunosuppressive roles of intravenous immunoglobulin (IVIg)

[1] A.F. Barahona Afonso, C.M. Joao, The Production Processes and Biological Effects

of Intravenous Immunoglobulin, Biomolecules 6 (2016) 15.

[2] A.W. Zuercher, R. Spirig, A. Baz Morelli, F. Kasermann, IVIG in autoimmune

disease - Potential next generation biologics, Autoimmun Rev 15 (2016)

781-785.

[3] V.B. E., Untersuchungen ueber das Zustandekommen der Diphtherie-Immunitat bei

Thieren (in Germany), Dtsch. Med. Wochenschr. 16 (1890) 1145-1148.

[4] V.B. E., K. S., Ueber das Zustandekommen der Diphtherie-Immunitat und der

Tetanus-Immunitat bei Thieren (in Germany), Dtsch. Med. Wochenschr. 16

(1890) 1113-1114.

[5] O.C. Bruton, Agammaglobulinemia, Pediatrics 9 (1952) 722-728.

[6] P. Imbach, S. Barandun, C. Baumgartner, A. Hirt, F. Hofer, H.P. Wagner, High-dose

intravenous gammaglobulin therapy of refractory, in particular idiopathic

thrombocytopenia in childhood, Helv Paediatr Acta 36 (1981) 81-86.

[7] L. Wang, F.S. Wang, M.E. Gershwin, Human autoimmune diseases: a

comprehensive update, J Intern Med 278 (2015) 369-395.

[8] M.R. Arbuckle, M.T. McClain, M.V. Rubertone, R.H. Scofield, G.J. Dennis, J.A.

James, J.B. Harley, Development of autoantibodies before the clinical onset of

systemic lupus erythematosus, N Engl J Med 349 (2003) 1526-1533.

[9] R. Jonsson, E. Theander, B. Sjostrom, K. Brokstad, G. Henriksson, Autoantibodies

present before symptom onset in primary Sjogren syndrome, Jama 310 (2013)

1854-1855.

[10] M.M. Nielen, D. van Schaardenburg, H.W. Reesink, R.J. van de Stadt, I.E. van der

60

Horst-Bruinsma, M.H. de Koning, M.R. Habibuw, J.P. Vandenbroucke, B.A.

Dijkmans, Specific autoantibodies precede the symptoms of rheumatoid

arthritis: a study of serial measurements in blood donors, Arthritis Rheum 50

(2004) 380-386.

[11] S. Kotake, N. Udagawa, N. Takahashi, K. Matsuzaki, K. Itoh, S. Ishiyama, S. Saito,

K. Inoue, N. Kamatani, M.T. Gillespie, T.J. Martin, T. Suda, IL-17 in synovial

fluids from patients with rheumatoid arthritis is a potent stimulator of

osteoclastogenesis, J Clin Invest 103 (1999) 1345-1352.

[12] D. Li, B. Guo, H. Wu, L. Tan, C. Chang, Q. Lu, Interleukin-17 in systemic lupus

erythematosus: A comprehensive review, Autoimmunity 48 (2015) 353-361.

[13] L.W. Zhang, P.R. Zhou, P. Wei, X. Cong, L.L. Wu, H. Hua, Expression of

interleukin-17 in primary Sjogren's syndrome and the correlation with disease

severity: A systematic review and meta-analysis, Scand J Immunol 87 (2018)

e12649.

[14] A. Waisman, J. Hauptmann, T. Regen, The role of IL-17 in CNS diseases, Acta

Neuropathol 129 (2015) 625-637.

[15] L.S. Walker, M. von Herrath, CD4 T cell differentiation in type 1 diabetes, Clin

Exp Immunol 183 (2016) 16-29.

[16] H. Kita, Z.X. Lian, J. Van de Water, X.S. He, S. Matsumura, M. Kaplan, V.

Luketic, R.L. Coppel, A.A. Ansari, M.E. Gershwin, Identification of

HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary

cirrhosis: T cell activation is augmented by immune complexes cross-presented

by dendritic cells, J Exp Med 195 (2002) 113-123.

[17] C. Scheinecker, M. Bonelli, J.S. Smolen, Pathogenetic aspects of systemic lupus

erythematosus with an emphasis on regulatory T cells, J Autoimmun 35 (2010)

269-275.

[18] K.M. Danikowski, S. Jayaraman, B.S. Prabhakar, Regulatory T cells in multiple

sclerosis and myasthenia gravis, J Neuroinflammation 14 (2017) 117.

61

[19] F.A. Cooles, J.D. Isaacs, A.E. Anderson, Treg cells in rheumatoid arthritis: an

update, Curr Rheumatol Rep 15 (2013) 352.

[20] J.W. Newburger, M. Takahashi, J.C. Burns, Kawasaki Disease, J Am Coll Cardiol

67 (2016) 1738-1749.

[21] J.W. Newburger, Kawasaki disease: Medical therapies, Congenit Heart Dis 12

(2017) 641-643.

[22] G. Zandman-Goddard, Y. Levy, Y. Shoenfeld, Intravenous immunoglobulin

therapy and systemic lupus erythematosus, Clin Rev Allergy Immunol 29 (2005)

219-228.

[23] R. Sakthiswary, D. D'Cruz, Intravenous immunoglobulin in the therapeutic

armamentarium of systemic lupus erythematosus: a systematic review and

meta-analysis, Medicine (Baltimore) 93 (2014) e86.

[24] J. Jellusova, L. Nitschke, Regulation of B cell functions by the sialic acid-binding

receptors siglec-G and CD22, Front Immunol 2 (2011) 96.

[25] J.F. Seite, D. Cornec, Y. Renaudineau, P. Youinou, R.A. Mageed, S. Hillion, IVIg

modulates BCR signaling through CD22 and promotes apoptosis in mature

human B lymphocytes, Blood 116 (2010) 1698-1704.

[26] T. Muta, T. Kurosaki, Z. Misulovin, M. Sanchez, M.C. Nussenzweig, J.V. Ravetch,

A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates

B-cell receptor signalling, Nature 368 (1994) 70-73.

[27] M. Ballow, The IgG molecule as a biological immune response modifier:

mechanisms of action of intravenous immune serum globulin in autoimmune

and inflammatory disorders, J Allergy Clin Immunol 127 (2011) 315-323.

[28] M.D. Kazatchkine, S.V. Kaveri, Immunomodulation of autoimmune and

inflammatory diseases with intravenous immune globulin, N Engl J Med 345

(2001) 747-755.

62

[29] A. Kessel, R. Peri, T. Haj, A. Snir, G. Slobodin, E. Sabo, I. Rosner, Y. Shoenfeld,

E. Toubi, IVIg attenuates TLR-9 activation in B cells from SLE patients, J Clin

Immunol 31 (2011) 30-38.

[30] J.F. Seite, T. Guerrier, D. Cornec, C. Jamin, P. Youinou, S. Hillion, TLR9

responses of B cells are repressed by intravenous immunoglobulin through the

recruitment of phosphatase, J Autoimmun 37 (2011) 190-197.

[31] V.K. Kuchroo, P.S. Ohashi, R.B. Sartor, C.G. Vinuesa, Dysregulation of immune

homeostasis in autoimmune diseases, Nat Med 18 (2012) 42-47.

[32] S.J. Kim, J.H. Won, B cell homeostasis and the development of chronic

graft-versus-host disease: implications for B cell-depleting therapy, Leuk

Lymphoma 53 (2012) 19-25.

[33] M. Wunsch, C. Hohmann, B. Milles, C. Rostermund, P.V. Lehmann, M. Schroeter,

A. Bayas, J. Ulzheimer, M. Maurer, S. Ergun, S. Kuerten, The Correlation

between the Virus- and Brain Antigen-Specific B Cell Response in the Blood of

Patients with Multiple Sclerosis, Viruses 8 (2016) 105.

[34] A. Pollreisz, A. Assinger, S. Hacker, K. Hoetzenecker, W. Schmid, G. Lang, M.

Wolfsberger, B. Steinlechner, E. Bielek, E. Lalla, W. Klepetko, I. Volf, H.J.

Ankersmit, Intravenous immunoglobulins induce CD32-mediated platelet

aggregation in vitro, Br J Dermatol 159 (2008) 578-584.

[35] Y. Kaneko, F. Nimmerjahn, J.V. Ravetch, Anti-inflammatory activity of

immunoglobulin G resulting from Fc sialylation, Science 313 (2006) 670-673.

[36] M. Mitrevski, R. Marrapodi, A. Camponeschi, F.M. Cavaliere, C. Lazzeri, L. Todi,

M. Visentini, Intravenous Immunoglobulin and Immunomodulation of B-Cell in vitro and in vivo Effects, Front Immunol 6 (2015) 4.

[37] P. Bjorck, S. Paulie, B. Axelsson, Interleukin-4-mediated aggregation of

anti-IgM-stimulated human B cells: inhibition of aggregation but enhancement

of proliferation by antibodies to LFA-1, Immunology 75 (1992) 122-128.

63

[38] C. Bossen, A. Tardivel, L. Willen, C.A. Fletcher, M. Perroud, F. Beermann, A.G.

Rolink, M.L. Scott, F. Mackay, P. Schneider, Mutation of the BAFF furin

cleavage site impairs B-cell homeostasis and antibody responses, Eur J Immunol

41 (2011) 787-797.

[39] V.T. Chu, P. Enghard, S. Schurer, G. Steinhauser, B. Rudolph, G. Riemekasten, C.

Berek, Systemic activation of the immune system induces aberrant BAFF and

APRIL expression in B cells in patients with systemic lupus erythematosus,

Arthritis Rheum 60 (2009) 2083-2093.

[40] E. Zollars, J. Bienkowska, J. Czerkowicz, N. Allaire, A.M. Ranger, L. Magder, M.

Petri, BAFF (B cell activating factor) transcript level in peripheral blood of

patients with SLE is associated with same-day disease activity as well as global

activity over the next year, Lupus Sci Med 2 (2015) e000063.

[41] X. Mariette, S. Roux, J. Zhang, D. Bengoufa, F. Lavie, T. Zhou, R. Kimberly, The

level of BLyS (BAFF) correlates with the titre of autoantibodies in human

Sjogren's syndrome, Ann Rheum Dis 62 (2003) 168-171.

[42] E. Claudio, K. Brown, S. Park, H. Wang, U. Siebenlist, BAFF-induced

NEMO-independent processing of NF-kappa B2 in maturing B cells, Nat

Immunol 3 (2002) 958-965.

[43] N. Kayagaki, M. Yan, D. Seshasayee, H. Wang, W. Lee, D.M. French, I.S. Grewal,

A.G. Cochran, N.C. Gordon, J. Yin, M.A. Starovasnik, V.M. Dixit, BAFF/BLyS

receptor 3 binds the B cell survival factor BAFF ligand through a discrete

surface loop and promotes processing of NF-kappaB2, Immunity 17 (2002)

515-524.

[44] J. Jellusova, A.V. Miletic, M.H. Cato, W.W. Lin, Y. Hu, G.A. Bishop, M.J.

Shlomchik, R.C. Rickert, Context-specific BAFF-R signaling by the NF-kappaB

and PI3K pathways, Cell Rep 5 (2013) 1022-1035.

[45] G. Recalde, T. Moreno-Sosa, F. Yudica, C.A. Quintero, M.B. Sanchez, G.A. Jahn,

A.M. Kalergis, J.P. Mackern-Oberti, Contribution of sex steroids and prolactin

to the modulation of T and B cells during autoimmunity, Autoimmun Rev 17

64

(2018) 504-512.

[46] E. Ortona, M. Pierdominici, A. Maselli, C. Veroni, F. Aloisi, Y. Shoenfeld,

Sex-based differences in autoimmune diseases, Ann Ist Super Sanita 52 (2016)

205-212.

[47] N. Kanda, K. Tamaki, Estrogen enhances immunoglobulin production by human

PBMCs, J Allergy Clin Immunol 103 (1999) 282-288.

[48] J. Correale, M.F. Farez, M.C. Ysrraelit, Role of prolactin in B cell regulation in

multiple sclerosis, J Neuroimmunol 269 (2014) 76-86.

[49] M. Dardenne, P.A. Kelly, J.F. Bach, W. Savino, Identification and functional

activity of prolactin receptors in thymic epithelial cells, Proc Natl Acad Sci U S

A 88 (1991) 9700-9704.

[50] P. Ascenzi, A. Bocedi, M. Marino, Structure-function relationship of estrogen

receptor alpha and beta: impact on human health, Mol Aspects Med 27 (2006)

299-402.

[51] C. Bole-Feysot, V. Goffin, M. Edery, N. Binart, P.A. Kelly, Prolactin (PRL) and its

receptor: actions, signal transduction pathways and phenotypes observed in PRL

receptor knockout mice, Endocr Rev 19 (1998) 225-268.

[52] V. Goffin, N. Binart, P. Clement-Lacroix, B. Bouchard, C. Bole-Feysot, M. Edery,

B.K. Lucas, P. Touraine, A. Pezet, R. Maaskant, C. Pichard, C. Helloco, N.

Baran, H. Favre, S. Bernichtein, A. Allamando, C. Ormandy, P.A. Kelly, From

the molecular biology of prolactin and its receptor to the lessons learned from

knockout mice models, Genet Anal 15 (1999) 189-201.

[53] D. Xiong, Y. Du, H.B. Wang, B. Zhao, H. Zhang, Y. Li, L.J. Hu, J.Y. Cao, Q.

Zhong, W.L. Liu, M.Z. Li, X.F. Zhu, S.W. Tsao, L.M. Hutt-Fletcher, E. Song,

Y.X. Zeng, E. Kieff, M.S. Zeng, Nonmuscle myosin heavy chain IIA mediates

Epstein-Barr virus infection of nasopharyngeal epithelial cells, Proc Natl Acad

Sci U S A 112 (2015) 11036-11041.

65

[54] A.S. De Groot, L. Moise, J.A. McMurry, E. Wambre, L. Van Overtvelt, P.

Moingeon, D.W. Scott, W. Martin, Activation of natural regulatory T cells by

IgG Fc-derived peptide "Tregitopes", Blood 112 (2008) 3303-3311.

[55] B.M. Fiebiger, J. Maamary, A. Pincetic, J.V. Ravetch, Protection in antibody- and

T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type

II FcRs, Proc Natl Acad Sci U S A 112 (2015) E2385-2394.

[56] J. Trinath, P. Hegde, M. Sharma, M.S. Maddur, M. Rabin, J.M. Vallat, L. Magy,

K.N. Balaji, S.V. Kaveri, J. Bayry, Intravenous immunoglobulin expands

regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin

E2 in human dendritic cells, Blood 122 (2013) 1419-1427.

[57] R.J. Brownlie, R. Zamoyska, T cell receptor signalling networks: branched,

diversified and bounded, Nat Rev Immunol 13 (2013) 257-269.

[58] M.L. Thomas, E.J. Brown, Positive and negative regulation of Src-family

membrane kinases by CD45, Immunol Today 20 (1999) 406-411.

[59] U. D'Oro, J.D. Ashwell, Cutting edge: the CD45 tyrosine phosphatase is an

inhibitor of Lck activity in thymocytes, J Immunol 162 (1999) 1879-1883.

[60] B.A. Freiberg, H. Kupfer, W. Maslanik, J. Delli, J. Kappler, D.M. Zaller, A.

Kupfer, Staging and resetting T cell activation in SMACs, Nat Immunol 3

(2002) 911-917.

[61] R. Varma, G. Campi, T. Yokosuka, T. Saito, M.L. Dustin, T cell receptor-proximal

signals are sustained in peripheral microclusters and terminated in the central

supramolecular activation cluster, Immunity 25 (2006) 117-127.

[62] J.F. Cote, K. Vuori, Identification of an evolutionarily conserved superfamily of

DOCK180-related proteins with guanine nucleotide exchange activity, J Cell Sci

115 (2002) 4901-4913.

[63] C.J. Kearney, K.L. Randall, J. Oliaro, DOCK8 regulates signal transduction events

to control immunity, Cell Mol Immunol 14 (2017) 406-411.

66

[64] S. Kumari, S. Vardhana, M. Cammer, S. Curado, L. Santos, M.P. Sheetz, M.L.

Dustin, T Lymphocyte Myosin IIA is Required for Maturation of the

Immunological Synapse, Front Immunol 3 (2012) 230.

[65] S. Xia, X. Zhang, S. Zheng, R. Khanabdali, B. Kalionis, J. Wu, W. Wan, X. Tai,

An Update on Inflamm-Aging: Mechanisms, Prevention, and Treatment, 2016

(2016) 8426874.

67

公表論文

(1) Anti-inflammatory intravenous immunoglobulin (IVIg) suppresses homeostatic

proliferation of B cells

Ayane Hori, Takashi Fujimura, and Seiji Kawamoto

Cytotechnology, 70, 921-927 (2018).

(2) Intravenous immunoglobulin (IVIg) acts directly on conventional T cells to

suppress T cell receptor signaling

Ayane Hori, Takashi Fujimura, Mai Murakami, Jungyeon Park, and Seiji

Kawamoto

Biochemical and Biophysical Research Communications, 522, 792-798 (2020).

参考論文

(1) Intake of a fermented plant product attenuates allergic symptoms without changing

systemic immune responses in a mouse model of Japanese cedar pollinosis.

Takashi Fujimura, Ayane Hori, Hideto Torii, Shinsuke Kishida, Yoshinori

Matsuura, and Seiji Kawamoto

World Allergy Organization Journal, 11, 31-39 (2018).

...